The Largest Personal Injury Firm in Texas. Serving Clients Nationwide.
Corpus Christi 361-985-0600 San Antonio 210-656-1000 Nationwide Toll Free 888-314-9945
Contact us 24/7

Gilead May be Ignoring Potential Hepatitis C Cure

View all
Staff Writer4 years ago

While studies show that the combination of sofosbuvir and declatasvir may provide a basis for a vialbe hepatitis C treatment, the HCV Coalition for the Cure is accusing big pharmaceutical company Gillead of putting profits before treating patients.

Good News Regarding New Hepatitis C Treatment

  • The good news is that we may have a potential cure for hepatitis C, the virus which attacks the liver and can often lead to liver cancer and death.
  • It comes in a combination of two drugs that showed in a study to clear 100% of the virus from forty different participants.
  • Although this is a small sample, keep in mind these forty patients had already failed Incivek and Victrelis treatments, the two leading therapies at the moment. That makes these forty participants the toughest in the world to target for a solution.

The Bad News Regarding New Hepatitis C Treatment

“Declatasvir and sofosbuvir looks much better but Gilead very clearly wants to develop in-house.” – Graham Cooke, Imperial College as published by Bloomberg.

  • The bad news is that each drug is owned by separate companies, and one does not want to play ball.
  • The uncooperative company in this story is Gilead, whose medication, sofosbuvir, was acquired through their buyout of Pharmasset.
  • Sofosbuvir has been a big investment for Gilead, and the patient advocates point out that the company is not likley looking to share the multi-billion dollar hepatitis C market.
  • As such, Gilead has elected to work on finding an in-house partner for sofosbuvir with ledispavir (GS-5885) being the companies current focus.
  • Experts like Graham Cooke with the Imperial College, however, worry that while the combonation of sofosbuvir and ledispavir may be succesful in treating hepatitis C genotype 1, it will likely be less efficient in treating hepatitis C genotype 3 than the declatasvir combonation.
Contact an Experience Clinical Trial Attorney

Thomas J. Henry are leaders in the area clinical trial litigation. Our Defective Drug and Products Division have extensive knowledge and resources in order to represent our clients efficiently and aggressively. Our Defective Drug and Products Division represent a multitude of people who are battling against manufacturers of medical devices and/or defective pharmaceuticals.

If you or a loved one have been injured by or have developed serious side-effects while participating in a clinical trial, contact Thomas J. Henry immediately. We represent clients/victims all over the country. We are available 24/7, nights and weekends.


Contact Us for a FREE Case Review

888-314-9945 •